Novo's diabetes drug liraglutide enters Alzheimer's trial
This article was originally published in Scrip
Executive Summary
Novo Nordisk's liraglutide, marketed as Victoza for the treatment of type 2 diabetes, could have a future as an Alzheimer's treatment, according to early research in mice conducted by Lancaster University, which has led the Alzheimer's Society, with support from Novo, to initiate human trials of the drug.